Integrating patient perspectives in medical decision-making: a qualitative interview study examining potentials within the rare disease information exchange process in practice

Abstract

Background Many European countries have recently implemented national rare disease plans. Although the network is strengthening, especially on the macro and meso levels, patients still go a long way through healthcare systems, with many health professionals involved and scarce evidence to gather. Specifically, patient involvement in the form of shared decision-making can offer further potential to increase healthcare systems’ efficiency on a micro level. Therefore, we examine the implementation of the shared decision-making concept thus far, and explore whether efficiency potentials exist—which are particularly relevant within the rare disease field—and how they can be triggered. Methods Our empirical evidence comes from 101 interviews conducted from March to September 2014 in Germany; 55 patients, 13 family members, and 33 health professionals participated in a qualitative interview study. Transcripts were analyzed using a directed qualitative content analysis. Results The interviews indicate that the decision-making process is increasingly relevant in practice. In comparison, however, the shared decision-making agreement itself was rarely reported. A majority of interactions are dominated by individual, informed decision-making, followed by paternalistic approaches. The patient-physician relationship was characterized by a distorted trust-building process, which is affected by not only dependencies due to the diseases’ severity and chronic course, but an often-reported stigmatization of patients as stimulants. Moreover, participation was high due to a pronounced engagement of those affected, diminishing as patients’ strength vanish during their odyssey through health care systems. The particular roles of “expert patients” or “lay experts” in the rare disease field were revealed, with further potential in integrating the gathered information. Conclusions The study reveals the named efficiency potentials, which are unique for rare diseases and make the further integration of shared decision-making very attractive, facilitating diagnostics and disease management. It is noteworthy that integrating shared decision-making in the rare disease field does not only require strengthening the position of patients but also that of physicians. Efforts can be made to further integrate the concept within political frameworks to trigger the identified potential and assess the health-economic impact.

The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: a narrative review

“…There is an urgent need for further original research into the experiences and expectations of patient advocates regarding therapeutic development. Such insights may later inform a decision-making framework to guide interactions between researchers and RDPOs [ 90 ].…”

Subjective Experience of Antidepressant Prescription Among Adolescents With Anorexia Nervosa

“…Consent to treatment and mental capacity to consent to treatment in anorexia are delicate concepts developed and debated in the literature (Turrell plus all coauthors 2011, Elzakkers plus all coauthors 2018). This complicates the question of the relevance of shared decision-making ( 39 ) and of the capacity of children and adolescents to make medical decisions for their health (Grootens-Wiegers plus all coauthors 2017).…”

Patient agency: key questions and challenges – A report from the 1st workshop of the EHC Think Tank Workstream on Patient Agency

“…Building trust between patients and HCPs is essential for a balanced and equal dialogue for SDM [9,12] , yet this can be challenging if there is a lack of continuity of care [13] . Clinicians need to be honest with patients and with themselves about what is known about a disease and its treatment and what is not.…”